Alexei Morozov

601 total citations
17 papers, 429 citations indexed

About

Alexei Morozov is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alexei Morozov has authored 17 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Alexei Morozov's work include Renal cell carcinoma treatment (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Ferroptosis and cancer prognosis (3 papers). Alexei Morozov is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Ferroptosis and cancer prognosis (3 papers). Alexei Morozov collaborates with scholars based in United States, Russia and Australia. Alexei Morozov's co-authors include Yildirim Dogan, Katia Manova‐Todorova, André L. Moreira, Sho Fujisawa, Malcolm A.S. Moore, Sepideh Gholami, Afşar Barlas, Emil Lou, Yevgeniy Romin and JeanMarie Houghton and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Alexei Morozov

15 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexei Morozov United States 6 241 123 60 58 55 17 429
Hong Seo Choi South Korea 12 272 1.1× 86 0.7× 49 0.8× 48 0.8× 46 0.8× 24 422
Radosław Szmyd Singapore 7 267 1.1× 136 1.1× 62 1.0× 48 0.8× 64 1.2× 9 508
Kristina Y. Aguilera United States 8 204 0.8× 195 1.6× 98 1.6× 47 0.8× 36 0.7× 16 484
Hongchen Cai United States 13 416 1.7× 185 1.5× 137 2.3× 42 0.7× 38 0.7× 18 579
S. Ashraf Imam United States 11 241 1.0× 177 1.4× 75 1.3× 32 0.6× 50 0.9× 25 530
Atsushi Terunuma United States 12 398 1.7× 120 1.0× 64 1.1× 96 1.7× 26 0.5× 23 659
Brian P. Danysh United States 12 328 1.4× 102 0.8× 38 0.6× 79 1.4× 24 0.4× 20 609
Pin‐Ji Lei United States 12 314 1.3× 138 1.1× 82 1.4× 38 0.7× 34 0.6× 24 508
Irene Raitman United States 6 291 1.2× 158 1.3× 154 2.6× 77 1.3× 53 1.0× 10 554
Rossana Lazcano United States 7 285 1.2× 141 1.1× 119 2.0× 167 2.9× 79 1.4× 19 593

Countries citing papers authored by Alexei Morozov

Since Specialization
Citations

This map shows the geographic impact of Alexei Morozov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexei Morozov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexei Morozov more than expected).

Fields of papers citing papers by Alexei Morozov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexei Morozov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexei Morozov. The network helps show where Alexei Morozov may publish in the future.

Co-authorship network of co-authors of Alexei Morozov

This figure shows the co-authorship network connecting the top 25 collaborators of Alexei Morozov. A scholar is included among the top collaborators of Alexei Morozov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexei Morozov. Alexei Morozov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Кушлинский, Н. Е., et al.. (2019). Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations. SHILAP Revista de lepidopterología. 15(1). 15–22. 7 indexed citations
2.
Kaysheva, Anna L., Arthur T. Kopylov, Н. Е. Кушлинский, et al.. (2019). Comparative Analysis of Blood Plasma Proteome in Patients with Renal Cell Carcinoma. Bulletin of Experimental Biology and Medicine. 167(1). 91–96. 4 indexed citations
3.
Кушлинский, Н. Е., et al.. (2019). Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma. Bulletin of Experimental Biology and Medicine. 166(3). 353–357. 18 indexed citations
4.
5.
Morozov, Alexei, et al.. (2019). DEVELOPMENT OF RECREATION AND TOURIST ACTIVITIES IN CONDITIONS OF CLIMATE CHANGE IN SOUTHERN REGION OF UKRAINE. Herald UNU International Economic Relations And World Economy. 1 indexed citations
6.
Кушлинский, Н. Е., et al.. (2018). Modern approaches to kidney cancer immunotherapy. Cancer Urology. 14(2). 54–67. 13 indexed citations
7.
8.
Немцова, М. В., et al.. (2017). MOLECULAR-GENETIC RESEARCH OF SPORADIC TUMORS OF THE KIDNEY. Tambov University Reports Series Natural and Technical Sciences. 22(6-2). 1405–1415. 1 indexed citations
9.
Герштейн, Е. С., et al.. (2017). Matrix metalloproteinases 2, 7, 8, 9 and their type 1 tissue inhibitor in serum of renal cancer patients: clinical and pathologic correlations. SHILAP Revista de lepidopterología. 45(2). 94–101. 5 indexed citations
10.
11.
Colombo, Nicoletta, Mary L. Disis, Keiichi Fujiwara, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial.. Journal of Clinical Oncology. 34(15_suppl). TPS5600–TPS5600. 6 indexed citations
12.
Ledermann, Jonathan A., Kei Fujiwara, I. Vergote, et al.. (2016). PHASE 3 TRIAL OF AVELUMAB (ANTI-PD-L1) IN COMBINATION WITH AND/OR FOLLOWING PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED OVARIAN CANCER. 1 indexed citations
13.
Lou, Emil, Sho Fujisawa, Alexei Morozov, et al.. (2012). Tunneling Nanotubes Provide a Unique Conduit for Intercellular Transfer of Cellular Contents in Human Malignant Pleural Mesothelioma. PLoS ONE. 7(3). e33093–e33093. 307 indexed citations
14.
Martell, Robert E., E. Gabriela Chiorean, Hagop Youssoufian, et al.. (2011). Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.. Journal of Clinical Oncology. 29(15_suppl). TPS150–TPS150. 3 indexed citations
15.
Morozov, Alexei. (2010). Hidden in Plain Sight. Science Translational Medicine. 2(36). 1 indexed citations
16.
Morozov, Alexei. (2010). Differentiation Block in Glioma. Science Translational Medicine. 2(33).
17.
Houghton, JeanMarie, et al.. (2006). Stem cells and cancer. Seminars in Cancer Biology. 17(3). 191–203. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hong Seo Choi Breakdown of academic impact, for papers by Radosław Szmyd Breakdown of academic impact, for papers by Kristina Y. Aguilera Breakdown of academic impact, for papers by Hongchen Cai Breakdown of academic impact, for papers by S. Ashraf Imam Breakdown of academic impact, for papers by Atsushi Terunuma Breakdown of academic impact, for papers by Brian P. Danysh Breakdown of academic impact, for papers by Pin‐Ji Lei Breakdown of academic impact, for papers by Irene Raitman Breakdown of academic impact, for papers by Rossana Lazcano
Rankless by CCL
2026